6,7-dihydropteridine reductase

6,7-Dihydropteridine reductase (DHPR) is an enzyme that plays a crucial role in the metabolism of folate and the regulation of monoamine neurotransmitters. This enzyme is involved in the biochemical pathway that converts biopterin, a cofactor for the synthesis of neurotransmitters, into its active form. The importance of DHPR in human health is underscored by its involvement in a rare, inherited metabolic disorder known as dihydropteridine reductase deficiency, which affects the body's ability to process certain amino acids and can lead to intellectual disability, movement disorders, and other severe neurological symptoms if not treated promptly.

Function

DHPR catalyzes the reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin (BH4), a critical cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases. These hydroxylases are necessary for the synthesis of the monoamine neurotransmitters dopamine, serotonin, and norepinephrine, which play significant roles in regulating mood, movement, and the autonomic nervous system. Therefore, the activity of DHPR is vital for maintaining normal neurotransmitter levels and function.

Genetic and Molecular Basis

The gene responsible for encoding DHPR is located on chromosome 11q23.3. Mutations in this gene can lead to dihydropteridine reductase deficiency, a condition characterized by elevated levels of phenylalanine in the blood and a deficiency of neurotransmitters. The diagnosis of this condition is typically made through newborn screening tests, which detect elevated phenylalanine levels, and confirmed by measuring DHPR activity in blood samples.

Clinical Significance

Dihydropteridine reductase deficiency is a form of hyperphenylalaninemia distinct from phenylketonuria (PKU), although both disorders result in elevated levels of phenylalanine. Unlike PKU, which is treated primarily through dietary restrictions, dihydropteridine reductase deficiency requires treatment with BH4 supplements and, in some cases, precursors to the deficient neurotransmitters. Early diagnosis and treatment are crucial to prevent neurological damage and improve outcomes.

Treatment and Management

The management of dihydropteridine reductase deficiency involves a combination of BH4 supplementation and dietary control to maintain low phenylalanine levels. Additionally, patients may require supplementation with L-dopa and 5-hydroxytryptophan, precursors to dopamine and serotonin, respectively, to address neurotransmitter deficiencies. Regular monitoring of phenylalanine levels, neurological function, and growth is essential for patients with this condition.

Research Directions

Research on DHPR and its associated genetic disorder continues to focus on understanding the molecular mechanisms underlying the enzyme's function and the pathophysiology of dihydropteridine reductase deficiency. Advances in gene therapy and enzyme replacement therapy hold promise for more effective treatments in the future. Additionally, studies on the regulation of DHPR activity and its role in neurotransmitter metabolism may provide insights into the treatment of other neurological and psychiatric disorders.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian